These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 17555867

  • 1. Glucocorticoids in the control of neuroinflammation.
    Tischner D, Reichardt HM.
    Mol Cell Endocrinol; 2007 Sep 15; 275(1-2):62-70. PubMed ID: 17555867
    [Abstract] [Full Text] [Related]

  • 2. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Reichardt HM, Gold R, Lühder F.
    Expert Rev Neurother; 2006 Nov 15; 6(11):1657-70. PubMed ID: 17144780
    [Abstract] [Full Text] [Related]

  • 3. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C.
    Inflammopharmacology; 2007 Oct 15; 15(5):183-7. PubMed ID: 17943249
    [Abstract] [Full Text] [Related]

  • 4. The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Fischer HJ, Schweingruber N, Lühder F, Reichardt HM.
    Mol Cell Endocrinol; 2013 Nov 05; 380(1-2):99-107. PubMed ID: 23578583
    [Abstract] [Full Text] [Related]

  • 5. Thalidomide derivatives for the treatment of neuroinflammation.
    Contino-Pépin C, Parat A, Patinote C, Roscoe WA, Karlik SJ, Pucci B.
    ChemMedChem; 2010 Dec 03; 5(12):2057-64. PubMed ID: 20936622
    [Abstract] [Full Text] [Related]

  • 6. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep 03; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 7. Combined treatment with atorvastatin and minocycline suppresses severity of EAE.
    Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi MC, Grossi C, Massacesi L, Casamenti F.
    Exp Neurol; 2008 May 03; 211(1):214-26. PubMed ID: 18346732
    [Abstract] [Full Text] [Related]

  • 8. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.
    Sriram S, Steiner I.
    Ann Neurol; 2005 Dec 03; 58(6):939-45. PubMed ID: 16315280
    [Abstract] [Full Text] [Related]

  • 9. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis.
    Kipp M, Beyer C.
    Front Neuroendocrinol; 2009 Jul 03; 30(2):188-200. PubMed ID: 19393685
    [Abstract] [Full Text] [Related]

  • 10. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators.
    Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM.
    J Neurol Sci; 2007 Aug 15; 259(1-2):79-84. PubMed ID: 17382965
    [Abstract] [Full Text] [Related]

  • 11. Antioxidant therapy in multiple sclerosis.
    Mirshafiey A, Mohsenzadegan M.
    Immunopharmacol Immunotoxicol; 2009 Aug 15; 31(1):13-29. PubMed ID: 18763202
    [Abstract] [Full Text] [Related]

  • 12. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Garay L, Gonzalez Deniselle MC, Gierman L, Meyer M, Lima A, Roig P, De Nicola AF.
    Neuroimmunomodulation; 2008 Aug 15; 15(1):76-83. PubMed ID: 18667803
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of glucocorticoids in the control of neuroinflammation.
    Schweingruber N, Reichardt SD, Lühder F, Reichardt HM.
    J Neuroendocrinol; 2012 Jan 15; 24(1):174-82. PubMed ID: 21615563
    [Abstract] [Full Text] [Related]

  • 14. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
    Heesen C, Gold SM, Huitinga I, Reul JM.
    Psychoneuroendocrinology; 2007 Jul 15; 32(6):604-18. PubMed ID: 17602841
    [Abstract] [Full Text] [Related]

  • 15. Lessons from multiple sclerosis: models, concepts, observations.
    Wekerle H.
    Ann Rheum Dis; 2008 Dec 15; 67 Suppl 3():iii56-60. PubMed ID: 19022815
    [Abstract] [Full Text] [Related]

  • 16. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D.
    Immunopharmacol Immunotoxicol; 2009 Dec 15; 31(1):32-8. PubMed ID: 18792835
    [Abstract] [Full Text] [Related]

  • 17. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy.
    Lühder F, Reichardt HM.
    Crit Rev Immunol; 2009 Dec 15; 29(3):255-73. PubMed ID: 19538138
    [Abstract] [Full Text] [Related]

  • 18. New insights into adaptive immunity in chronic neuroinflammation.
    Siffrin V, Brandt AU, Herz J, Zipp F.
    Adv Immunol; 2007 Dec 15; 96():1-40. PubMed ID: 17981203
    [Abstract] [Full Text] [Related]

  • 19. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr 15; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 20. Idazoxan attenuates spinal cord injury by enhanced astrocytic activation and reduced microglial activation in rat experimental autoimmune encephalomyelitis.
    Wang XS, Chen YY, Shang XF, Zhu ZG, Chen GQ, Han Z, Shao B, Yang HM, Xu HQ, Chen JF, Zheng RY.
    Brain Res; 2009 Feb 09; 1253():198-209. PubMed ID: 19083996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.